JP2023511417A5 - - Google Patents
Info
- Publication number
- JP2023511417A5 JP2023511417A5 JP2022544717A JP2022544717A JP2023511417A5 JP 2023511417 A5 JP2023511417 A5 JP 2023511417A5 JP 2022544717 A JP2022544717 A JP 2022544717A JP 2022544717 A JP2022544717 A JP 2022544717A JP 2023511417 A5 JP2023511417 A5 JP 2023511417A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- chain variable
- variable domain
- alpha
- beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025054385A JP2025092600A (ja) | 2020-01-24 | 2025-03-27 | 黒色腫において優先的に発現する抗原（ｐｒａｍｅ）ｔ細胞受容体およびそれらの使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062965231P | 2020-01-24 | 2020-01-24 | |
| US62/965,231 | 2020-01-24 | ||
| PCT/US2021/014490 WO2021150804A1 (en) | 2020-01-24 | 2021-01-22 | Preferentially expressed antigen in melanoma (prame) t cell receptors and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025054385A Division JP2025092600A (ja) | 2020-01-24 | 2025-03-27 | 黒色腫において優先的に発現する抗原（ｐｒａｍｅ）ｔ細胞受容体およびそれらの使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023511417A JP2023511417A (ja) | 2023-03-17 |
| JP2023511417A5 true JP2023511417A5 (https=) | 2024-01-25 |
Family
ID=74592833
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544717A Withdrawn JP2023511417A (ja) | 2020-01-24 | 2021-01-22 | 黒色腫において優先的に発現する抗原（ｐｒａｍｅ）ｔ細胞受容体およびそれらの使用方法 |
| JP2025054385A Pending JP2025092600A (ja) | 2020-01-24 | 2025-03-27 | 黒色腫において優先的に発現する抗原（ｐｒａｍｅ）ｔ細胞受容体およびそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025054385A Pending JP2025092600A (ja) | 2020-01-24 | 2025-03-27 | 黒色腫において優先的に発現する抗原（ｐｒａｍｅ）ｔ細胞受容体およびそれらの使用方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230060095A1 (https=) |
| EP (1) | EP4093753A1 (https=) |
| JP (2) | JP2023511417A (https=) |
| KR (1) | KR20220131956A (https=) |
| CN (1) | CN115427436A (https=) |
| AU (1) | AU2021211485A1 (https=) |
| BR (1) | BR112022014461A2 (https=) |
| CA (1) | CA3165827A1 (https=) |
| CL (3) | CL2022001975A1 (https=) |
| CO (1) | CO2022011869A2 (https=) |
| IL (1) | IL294988A (https=) |
| MX (1) | MX2022009137A (https=) |
| PH (1) | PH12022551857A1 (https=) |
| WO (1) | WO2021150804A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113621070A (zh) | 2020-05-06 | 2021-11-09 | 华夏英泰（北京）生物技术有限公司 | 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用 |
| GB202218754D0 (en) * | 2022-12-13 | 2023-01-25 | Adaptimmune Ltd | T cell receptor |
| GB202219294D0 (en) * | 2022-12-20 | 2023-02-01 | Nextera As | Antigen binding proteins |
| WO2024146951A1 (en) * | 2023-01-06 | 2024-07-11 | Immunocore Limited | Binding molecules against a prame peptide-hla complex |
| WO2024148397A1 (en) * | 2023-01-09 | 2024-07-18 | Myrio Therapeutics Pty Ltd | Binding agents for prame peptide-mhc complex |
| CN116715750B (zh) * | 2023-03-14 | 2024-04-12 | 新景智源生物科技(苏州)有限公司 | 特异性识别prame抗原的tcr及其与cd8共表达来重定向cd4 t细胞 |
| CN118047853B (zh) * | 2023-06-28 | 2024-11-15 | 立凌生物制药(苏州)有限公司 | 识别肿瘤相关抗原的tcr分子及其用途 |
| CN118221811B (zh) * | 2023-08-25 | 2025-05-30 | 立凌生物制药(苏州)有限公司 | 靶向prame多肽的单域抗体及其用途 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL79289A (en) | 1985-07-05 | 1992-01-15 | Whitehead Biomedical Inst | Introduction and expression of foreign genetic material into keratinocytes using a recombinant retrovirus |
| US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
| US4690915A (en) | 1985-08-08 | 1987-09-01 | The United States Of America As Represented By The Department Of Health And Human Services | Adoptive immunotherapy as a treatment modality in humans |
| ATE117375T1 (de) | 1987-09-11 | 1995-02-15 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
| JP2914692B2 (ja) | 1987-12-11 | 1999-07-05 | ホワイトヘツド・インスチチユート・フオー・バイオメデイカル・リサーチ | 内皮細胞の遺伝子修飾 |
| WO1989007136A2 (en) | 1988-02-05 | 1989-08-10 | Whitehead Institute For Biomedical Research | Modified hepatocytes and uses therefor |
| ES2096750T3 (es) | 1990-10-31 | 1997-03-16 | Somatix Therapy Corp | Vectores retroviricos utiles para la terapia genica. |
| WO1999060120A2 (en) | 1998-05-19 | 1999-11-25 | Avidex Limited | Soluble t cell receptor |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| KR20030032922A (ko) | 2000-02-24 | 2003-04-26 | 싸이트 테라피스 인코포레이티드 | 세포의 동시 자극 및 농축 |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US20030170238A1 (en) | 2002-03-07 | 2003-09-11 | Gruenberg Micheal L. | Re-activated T-cells for adoptive immunotherapy |
| US9281917B2 (en) | 2007-01-03 | 2016-03-08 | Nokia Technologies Oy | Shared control channel structure |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| PL228457B1 (pl) | 2013-08-30 | 2018-03-30 | Univ Jagiellonski | Tomograf hybrydowy TOF-PET/CT |
| IL297773B2 (en) | 2014-11-17 | 2024-07-01 | Adicet Bio Inc | Engineered gamma delta t-cells |
| CA2978171A1 (en) * | 2015-03-10 | 2016-09-15 | J.H. Frederik Falkenburg | T-cell receptors directed against the preferentially expressed antigen of melanoma and uses thereof |
| EP4248744A3 (en) | 2015-04-06 | 2023-12-27 | Regeneron Pharmaceuticals, Inc. | Humanized t cell mediated immune responses in non-human animals |
| DE102017106305A1 (de) * | 2017-03-23 | 2018-09-27 | Immatics Biotechnologies Gmbh | Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten |
| US11236145B2 (en) * | 2017-03-23 | 2022-02-01 | Immatics Biotechnologies Gmbh | T cell receptors and immune therapy using the same against PRAME positive cancers |
| GB201709866D0 (en) * | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
-
2021
- 2021-01-22 EP EP21705081.4A patent/EP4093753A1/en active Pending
- 2021-01-22 AU AU2021211485A patent/AU2021211485A1/en active Pending
- 2021-01-22 CA CA3165827A patent/CA3165827A1/en active Pending
- 2021-01-22 PH PH1/2022/551857A patent/PH12022551857A1/en unknown
- 2021-01-22 WO PCT/US2021/014490 patent/WO2021150804A1/en not_active Ceased
- 2021-01-22 MX MX2022009137A patent/MX2022009137A/es unknown
- 2021-01-22 JP JP2022544717A patent/JP2023511417A/ja not_active Withdrawn
- 2021-01-22 BR BR112022014461A patent/BR112022014461A2/pt unknown
- 2021-01-22 IL IL294988A patent/IL294988A/en unknown
- 2021-01-22 KR KR1020227028683A patent/KR20220131956A/ko active Pending
- 2021-01-22 US US17/793,952 patent/US20230060095A1/en active Pending
- 2021-01-22 CN CN202180023291.4A patent/CN115427436A/zh active Pending
-
2022
- 2022-07-21 CL CL2022001975A patent/CL2022001975A1/es unknown
- 2022-08-22 CO CONC2022/0011869A patent/CO2022011869A2/es unknown
-
2024
- 2024-04-18 CL CL2024001224A patent/CL2024001224A1/es unknown
-
2025
- 2025-03-27 JP JP2025054385A patent/JP2025092600A/ja active Pending
- 2025-09-05 CL CL2025002714A patent/CL2025002714A1/es unknown